Company Profile
Tarsus Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- TARS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
65.33 USD (+6.59%)
Close
Last updated: August 6, 2026
2.47B USD
Market cap
Why the stock is moving
Following the latest company update, “Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth”, TARS closed up 6.59% at $65.33 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Eye-Care Therapeutics
Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications.
XDEMVY
XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a six-week treatment course and anchors the company's commercial franchise.
TP-04
TP-04 is a sterile ophthalmic-gel formulation of lotilaner in Phase 2 development for ocular rosacea.
TP-05
TP-05 is an oral lotilaner formulation designed to kill ticks before they transmit infection, creating a prophylactic approach to Lyme disease.
Future catalysts
Topline Phase 2 data for TP-04 in ocular rosacea in the first half of 2027.
Topline Phase 2 Calliope data for TP-05 in Lyme-disease prevention in the first half of 2027.
Recent news
- 01
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Source: Tarsus Pharmaceuticals
- 02
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
Source: Tarsus Pharmaceuticals
- 03
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
Source: Tarsus Pharmaceuticals
- 04
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Source: Tarsus Pharmaceuticals
- 05
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
Source: Tarsus Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmaceuticals (TARS) most recently closed at 65.33 USD, a +6.59% move versus the previous session.
What is the market cap of Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmaceuticals currently has a market capitalization of 2.47B USD on BioPharmSignal.
What does Tarsus Pharmaceuticals do?
Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a six-week treatment...
On which exchange is TARS stock listed?
Tarsus Pharmaceuticals (TARS) is associated with NASDAQ, United States, Biopharma.
What is TP-04?
Topline Phase 2 data for TP-04 in ocular rosacea in the first half of 2027.
Which conditions is Tarsus Pharmaceuticals targeting with TP-04?
Topline Phase 2 data for TP-04 in ocular rosacea in the first half of 2027.
How does Tarsus Pharmaceuticals describe recent progress with TP-04?
Topline Phase 2 data for TP-04 in ocular rosacea in the first half of 2027.
What is TP-05?
TP-05 TP-05 is an oral lotilaner formulation designed to kill ticks before they transmit infection, creating a prophylactic approach to Lyme disease.